Zimmer pays $13.35bn in cash and stock for Biomet
Positioning itself to become a top competitor in the $45bn musculoskeletal market, Zimmer Holdings Inc. bought public orthopedic device maker Biomet Inc. for $13.35bn--$10.35bn in cash and $3bn in Zimmer stock. Zimmer plans to refinance some of its own debt, including an existing $250mm in notes due 2014, in addition to certain Biomet debt.
- Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.